Trials / Completed
CompletedNCT02438826
A Study of Galcanezumab in Participants With Chronic Cluster Headache
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of : Galcanezumab (LY2951742) With a Long-Term Open-Label Extension in Patients With Chronic Cluster Headache
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 240 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to evaluate the efficacy of the study drug known as galcanezumab in participants with chronic cluster headache.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Galcanezumab 300 mg | Administered SC |
| DRUG | Placebo | Administered SC |
Timeline
- Start date
- 2015-06-18
- Primary completion
- 2018-03-27
- Completion
- 2019-08-14
- First posted
- 2015-05-08
- Last updated
- 2020-08-25
- Results posted
- 2019-06-11
Locations
48 sites across 12 countries: United States, Belgium, Canada, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT02438826. Inclusion in this directory is not an endorsement.